Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 · kind B2 · utility
1Cited by
2References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2005 |
| Grant date | May 27, 2008 |
| Priority date | — |
| Expiry date | Feb 3, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are fused heterotricyclic compounds of the following formula I,or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of A ring or C ring is a 5-7 membered unsaturated heterocyclic ring. The disclosed compounds are useful as inhibitors of 17β-hydroxysteroid dehydrogenase 3 (17β-HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions comprising such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.